These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17171433)

  • 1. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease.
    Auray-Blais C; Cyr D; Mills K; Giguère R; Drouin R
    J Inherit Metab Dis; 2007 Feb; 30(1):106. PubMed ID: 17171433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.
    Mills K; Morris P; Lee P; Vellodi A; Waldek S; Young E; Winchester B
    J Inherit Metab Dis; 2005; 28(1):35-48. PubMed ID: 15702404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months.
    Barr C; Clarke JT; Ntwari A; Drouin R; Auray-Blais C
    Mol Genet Metab; 2009 Aug; 97(4):278-83. PubMed ID: 19464216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb
    Auray-Blais C; Lavoie P; Boutin M; Abaoui M
    Curr Protoc Hum Genet; 2017 Apr; 93():17.26.1-17.26.12. PubMed ID: 28384397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
    Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
    Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is globotriaosylceramide a useful biomarker in Fabry disease?
    Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
    Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
    Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
    J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
    Piraud M; Maire I; Froissart R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.
    Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL
    Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease.
    Fuller M; Lovejoy M; Brooks DA; Harkin ML; Hopwood JJ; Meikle PJ
    Clin Chem; 2004 Nov; 50(11):1979-85. PubMed ID: 15364892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.
    Kitagawa T; Suzuki K; Ishige N; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Odaka H; Owada M
    Pediatr Nephrol; 2008 Sep; 23(9):1461-71. PubMed ID: 18535844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
    Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
    Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
    Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
    Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
    Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
    J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
    Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ
    Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
    Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
    Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients.
    Auray-Blais C; Lavoie P; Abaoui M; Côté AM; Boutin M; Akbari A; Levin A; Mac-Way F; Tr Clarke J
    Clin Chim Acta; 2020 Feb; 501():234-240. PubMed ID: 31778673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.